التفاصيل البيبلوغرافية
| العنوان: |
Ticagrelor and CABG for acute coronary syndrome?-It is complicated. |
| المؤلفون: |
Sandner, Sigrid1 (AUTHOR), Gaudino, Mario2 (AUTHOR) mfg9004@med.cornell.edu |
| المصدر: |
Journal of Cardiac Surgery. Aug2021, Vol. 36 Issue 8, p2802-2804. 3p. |
| مصطلحات موضوعية: |
*ACUTE coronary syndrome, *TICAGRELOR, *CORONARY artery bypass, *MYOCARDIAL infarction, *ATHEROSCLEROSIS, *REOPERATION, *CORONARY artery disease |
| مستخلص: |
Given the lack of established benefit, routine P2Y12 receptor inhibitor pretreatment in NSTE-ACS is not recommended in patients in whom the coronary anatomy is not known and early invasive management is planned, although it may be considered for patients with delayed invasive management.3 However, P2Y12 receptor inhibitor pretreatment may increase bleeding risk and delay surgery after diagnostic angiography in patients for whom CABG is indicated. In addition, in studies investigating the association of P2Y12 receptor inhibitors and perioperative bleeding risk a surgical bleeding site was identified in up to 55% of patients undergoing reoperation for bleeding,5,14 potentially confounding reports of increased bleeding with ticagrelor. Hansson et al.10 studied the incidence of CABG-related bleeding using the Bleeding Academic Research Consortium (BARC) classification11 in relation to P2Y12 receptor inhibitor discontinuation periods in a retrospective analysis of 2244 ACS patients referred for CABG on DAPT with either ticagrelor or clopidogrel. [Extracted from the article] |
| قاعدة البيانات: |
Academic Search Index |
